Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
According to the Global Burden of Disease study, in the US, between 1990 and 2021, obesity prevalence more than doubled in adults and almost tripled in adolescents
and grant support from Novo Nordisk and Boehringer Ingelheim
Composition 5-amino-1MQ: 5 mg Appearance: lyophilized powder in a sealed research vial Research Focus (non-clinical) Investigation of NNMT inhibition and its downstream metabolic effects Studies on NAD+ metabolism and energy homeostasis in preclinical models Development of analytical methods for small-molecule quantitation Stability and solubility assessment of 5-amino-1MQ under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
Conclusions There is consistent preclinical evidence that GLP-1R agonists are effective in reducing A levels and hyperphosphorylated tau
In other words, weight loss results in an improvement in muscle composition but a decline in muscle volume
